Rathbones Group PLC Buys 12,375 Shares of Guardant Health, Inc. (NASDAQ:GH)

Rathbones Group PLC boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 198,961 shares of the company's stock after purchasing an additional 12,375 shares during the quarter. Rathbones Group PLC owned about 0.16% of Guardant Health worth $6,078,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Bank of Montreal Can acquired a new position in shares of Guardant Health in the fourth quarter valued at approximately $248,000. Federated Hermes Inc. grew its holdings in Guardant Health by 11.5% in the 4th quarter. Federated Hermes Inc. now owns 962,722 shares of the company's stock valued at $29,411,000 after buying an additional 99,072 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Guardant Health in the 4th quarter valued at $420,000. Trexquant Investment LP lifted its holdings in shares of Guardant Health by 4.1% during the fourth quarter. Trexquant Investment LP now owns 474,171 shares of the company's stock worth $14,486,000 after buying an additional 18,461 shares in the last quarter. Finally, California Public Employees Retirement System lifted its holdings in shares of Guardant Health by 13.8% during the fourth quarter. California Public Employees Retirement System now owns 178,470 shares of the company's stock worth $5,452,000 after buying an additional 21,674 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Guardant Health Trading Up 6.2 %

NASDAQ:GH traded up $2.57 on Friday, reaching $43.71. 2,167,377 shares of the stock traded hands, compared to its average volume of 2,142,927. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89. The company's 50 day moving average is $43.57 and its 200-day moving average is $35.78. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -12.28 and a beta of 1.45.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GH has been the topic of a number of recent research reports. Canaccord Genuity Group raised their price target on shares of Guardant Health from $42.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. Stephens reiterated an "overweight" rating and issued a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. Stifel Nicolaus boosted their price target on Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Barclays lowered their price objective on Guardant Health from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday. Finally, Guggenheim reiterated a "buy" rating and set a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Twenty research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Guardant Health has a consensus rating of "Buy" and an average target price of $49.00.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.